ESALY News and Press, Eisai Co. Ltd. ADR From 12/19/22

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) will acquire the U.S. rights to Eisai's ( OTCPK:ESALY ) epilepsy drug Fycompa (perampanel) as well as a period to review and negotiate the acquisition of a rare epilepsy asset in the Japanese drugmaker's pipeline. Terms calls for Eisai (...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Major indices such as the  S&P 500  and the  Nasdaq Composite  may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of...

Summary Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer's disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically s...

Summary BioVie’s NE3107 has now shown improvement of cognition and function on different Alzheimer’s rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson’s disease with the same dru...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks overall have fared well during this tough year for the market, but Eli Lilly (NYSE: LLY ) has been a pharma name that’s truly “crushed it” so far in 2022. LLY stock has rallied 36....

ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE PR Newswire TOKYO and CAMBRIDGE, Mass. , No...

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE PR Newswire TOKYO and CAMBRIDGE, Mass. , Nov. 29, 2022 /PRNewswire/ -- Eisai Co., Ltd. (He...

Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Amer...

Call Start: 02:00 Call End: 03:28 Eisai Co., Ltd. (ESALF) Q2 2023 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Al...

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH TOKYO, Nov 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myona...